Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer.
Rachel L MinneNatalie Y LuoAnne M TraynorMinxuan HuangLuisina DeTullioJen GoddenMelissa StopplerRandall J KimpleAndrew M Baschnagel
Published in: Clinical lung cancer (2024)
METex14 tumors exhibited differences in IO biomarkers and the somatic landscape compared to non-METex14 NSCLC tumors. Variations in immune profiles can affect immunotherapy selection in MET-altered NSCLC and require further exploration.